At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 110 enrolled
Drug / intervention
Tranexamic Aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reducing Hemarthrosis in Anterior Cruciate Ligament Reconstruction With BTB Autograft by the Administration of Intravenous Tranexamic Acid: A Double-Blind Randomized Control Study
In Brief
A Phase 4 clinical trial evaluating Tranexamic Acid for Anterior Cruciate Ligament Reconstruction. Completed, enrolled 110 participants across 1 site.
Detailed Summary
The purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (TXA) to patients undergoing anterior cruciate ligament (ACL) reconstruction with bone-patellar tendon-bone autograft to minimize hemarthrosis within the knee joint and post operative pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedAug 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedAug 15, 2018
Enrollment StartJun 6, 2018
Primary CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.9 years ago
Interventions
Tranexamic Aciddrug
One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.